BioNTech (NASDAQ:BNTX) Price Target Raised to $150.00

BioNTech (NASDAQ:BNTX) had its price target upped by Deutsche Bank Aktiengesellschaft from $95.00 to $150.00 in a report published on Thursday, Benzinga reports. The firm currently has a buy rating on the stock.

Several other equities analysts have also recently commented on BNTX. Jefferies Financial Group raised shares of BioNTech from a hold rating to a buy rating and raised their price target for the company from $96.00 to $150.00 in a research report on Tuesday, September 17th. JPMorgan Chase & Co. upgraded BioNTech from an underweight rating to a neutral rating and lifted their target price for the company from $91.00 to $125.00 in a report on Monday, September 16th. UBS Group boosted their target price on BioNTech from $97.00 to $131.00 and gave the stock a neutral rating in a research note on Wednesday, September 18th. HSBC raised BioNTech from a hold rating to a buy rating in a research report on Friday, August 2nd. Finally, HC Wainwright reiterated a buy rating and issued a $113.00 price target on shares of BioNTech in a research note on Monday, September 16th. Six analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of Moderate Buy and a consensus target price of $124.54.

BioNTech Price Performance

BNTX opened at $112.28 on Thursday. The stock’s 50-day moving average price is $90.81 and its 200 day moving average price is $90.62. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The firm has a market cap of $26.69 billion, a price-to-earnings ratio of 224.56 and a beta of 0.23. The company has a current ratio of 7.54, a quick ratio of 7.40 and a debt-to-equity ratio of 0.01.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings results on Monday, August 5th. The company reported ($3.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.02) by ($1.34). BioNTech had a negative return on equity of 2.54% and a negative net margin of 18.69%. The business had revenue of $128.70 million for the quarter, compared to analysts’ expectations of $134.98 million. During the same quarter last year, the company earned ($0.86) earnings per share. The firm’s revenue for the quarter was down 23.3% on a year-over-year basis. As a group, sell-side analysts expect that BioNTech will post -2.8 earnings per share for the current year.

Hedge Funds Weigh In On BioNTech

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Dynamic Technology Lab Private Ltd grew its stake in shares of BioNTech by 2.5% in the 4th quarter. Dynamic Technology Lab Private Ltd now owns 4,666 shares of the company’s stock valued at $492,000 after purchasing an additional 116 shares during the last quarter. Covestor Ltd lifted its holdings in shares of BioNTech by 47.2% during the first quarter. Covestor Ltd now owns 415 shares of the company’s stock worth $38,000 after purchasing an additional 133 shares during the period. GAMMA Investing LLC grew its position in BioNTech by 121.0% in the 1st quarter. GAMMA Investing LLC now owns 274 shares of the company’s stock valued at $25,000 after buying an additional 150 shares during the last quarter. Midwest Professional Planners LTD. increased its stake in BioNTech by 7.2% in the 1st quarter. Midwest Professional Planners LTD. now owns 3,177 shares of the company’s stock valued at $293,000 after buying an additional 212 shares during the period. Finally, Capital International Ltd. CA raised its position in BioNTech by 1.0% during the 4th quarter. Capital International Ltd. CA now owns 21,066 shares of the company’s stock worth $2,223,000 after buying an additional 216 shares during the last quarter. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.